We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2019 to May 2024
By Adria Calatayud
AstraZeneca PLC said Monday that its Calquence drug showed greater safety than an existing drug without compromising efficacy in a phase 3 trial with adults with previously treated, high-risk chronic lymphocytic leukemia.
The British pharmaceutical giant said Calquence met the primary goal of demonstrating noninferior progression-free survival in a head-to-head trial against existing drug ibrutinib.
The drug also met a secondary goal for safety, showing patients treated with Calquence had statistically significantly lower incidence of atrial fibrillation compared with patients treated with ibrutinib, AstraZeneca said.
"The totality of the data confirm our confidence in the favourable benefit-risk profile of Calquence," AstraZeneca's Executive Vice President Jose Baselga said.
Write to Adria Calatayud at adria.calatayud@dowjones.com
(END) Dow Jones Newswires
January 25, 2021 02:29 ET (07:29 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
